BTS Appointed Exclusive Global A2P SMS Aggregator for BBIX and SoftBank Corp.
Business Telecommunications Services, Inc. (BTS), a leading provider, technology enabler, and trusted partner to CommTech players, has today announced its appointment as the exclusive international A2P SMS aggregator for BBIX, Inc. (BBIX), a wholly-owned subsidiary and the official international A2P SMS gateway of SoftBank Corp. (SoftBank). This agreement marks a significant milestone in the five-year partnership between BTS, BBIX, and SoftBank, enabling seamless and innovative international communication solutions.
As the exclusive aggregator, BTS will be the official channel for terminating international A2P SMS traffic to the SoftBank network. This partnership mandates all communications providers to route their traffic destined for SoftBank through BTS, ensuring seamless and secure delivery. By leveraging the complementary strengths of each company, this partnership enhances the global messaging ecosystem with improved operational efficiencies, enabling a better customer experience and more responsive customer support.
BTS's extensive global footprint and BBIX's market expertise will help partners navigate complex regulatory environments, expand market reach, and unlock cross-selling opportunities that can drive higher revenue growth. The partnership also ensures the delivery of secure and reliable messaging services by leveraging BTS’s advanced S1 Platform.
“As a trusted partner, we are pleased to expand our collaboration with BTS to ensure the seamless aggregation of global A2P SMS traffic,” said Hideyuki Sasaki, President & CEO of BBIX. “By combining our strengths and complementary expertise, we are delivering a secure and reliable solution that enhances the SoftBank network and supports the evolving needs of our global partners.”
“As a trusted partner and joint venture collaborator, BTS has consistently demonstrated the capabilities and expertise we need to support SoftBank’s global communications strategy,” commented Norioki Sekiguchi, Vice President of SoftBank Corp.’s Global Business Division. “By leveraging BBIX as our official gateway, BTS will ensure the seamless and secure aggregation of international A2P SMS traffic to our network, enabling us to deliver greater reliability and performance for our customers worldwide.”
This agreement solidifies BTS’s leadership in the global messaging space and underscores the ongoing collaboration between BTS, BBIX, and SoftBank. Together, they continue to pioneer innovative and scalable solutions that address the dynamic needs of the global communications industry.
“Becoming the exclusive aggregator of A2P SMS for BBIX and SoftBank marks an important milestone in our partnership, which began over five years ago,” concluded Andrés Proaño, EVP & CRO of BTS. “This collaboration reflects the strength of our relationship and our shared commitment to driving innovation in global communications. With many more strategic initiatives ahead, such as Open Connectivity eXchange (OCX), Roaming Peering eXchange (RPX), and advanced AI solutions, this agreement is a key step forward in a partnership poised for even greater growth and success.”
About BTS
BTS is a leading global provider, technology enabler, and trusted partner to CommTech players. Leveraging its proprietary S1 Platform and an international network of 400+ direct partners, BTS delivers advanced AI-driven solutions specializing in voice, messaging, cloud communications, and innovative services that drive growth for MNOs, carriers, digital players, and hyperscalers. BTS powers 18+ billion voice minutes annually across 180+ countries, with extensive cloud telephony coverage in 90+ hard-to-reach markets and global reach for messaging services.
About BBIX
BBIX was established in 2003 to be a carrier-free internet exchange (IX) provider headquartered in Japan and serving Asia, Europe, and the US. It provides various connectivity services such as IX, Roaming Peering eXchange (RPX), Open Connectivity eXchange (OCX), as well as A2P SMS solutions. BBIX has established itself as one of the leading IXs in Asia, with a growing membership and an expanding global footprint.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250119536400/en/
Contacts
Media Contact
Paula Ruiz
BTS Communications Team
pruiz@bts.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press Release
Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title sponsor of this caliber as we launch into year two as an ATP 500 event continues to elevate our tournament on the gl
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press Release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press Release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press Release
HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Crespo (Pigment), and senior leaders from global brands like Diageo, Disney, and Replit. Additional speakers represent over 20 AI unicorns, including Quantexa, Owkin, an
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press Release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom